Guggenheim Issues Pessimistic Forecast for Insmed (NASDAQ:INSM) Stock Price

Insmed (NASDAQ:INSM) had its price objective decreased by Guggenheim from $230.00 to $221.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s target price suggests a potential upside of 11.36% from the stock’s current price.

Several other analysts have also recently commented on the stock. William Blair started coverage on shares of Insmed in a report on Wednesday, August 20th. They set an “outperform” rating for the company. Redburn Partners set a $263.00 target price on shares of Insmed in a research report on Thursday, December 4th. Cowen restated a “buy” rating on shares of Insmed in a report on Wednesday, December 10th. Rothschild & Co Redburn began coverage on Insmed in a report on Thursday, December 4th. They set a “buy” rating and a $263.00 price objective for the company. Finally, Wolfe Research set a $167.00 price objective on Insmed and gave the company an “outperform” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $198.70.

Insmed Trading Down 1.1%

NASDAQ INSM opened at $198.46 on Thursday. The firm’s 50 day moving average price is $187.37 and its two-hundred day moving average price is $142.14. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. Insmed has a twelve month low of $60.40 and a twelve month high of $212.75. The stock has a market cap of $42.33 billion, a price-to-earnings ratio of -32.06 and a beta of 1.01.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The business had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The business’s quarterly revenue was up 52.4% on a year-over-year basis. During the same period last year, the business earned ($1.27) EPS. Equities analysts anticipate that Insmed will post -4.56 EPS for the current year.

Insider Buying and Selling

In related news, insider Michael Alexander Smith sold 27,130 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $183.78, for a total value of $4,985,951.40. Following the transaction, the insider directly owned 54,902 shares of the company’s stock, valued at approximately $10,089,889.56. This trade represents a 33.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Orlov S. Nicole Schaeffer sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $194.00, for a total value of $5,820,000.00. Following the sale, the insider directly owned 36,461 shares of the company’s stock, valued at $7,073,434. The trade was a 45.14% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 147,130 shares of company stock valued at $28,480,051 over the last 90 days. 3.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. grew its holdings in Insmed by 9.2% in the 1st quarter. Raymond James Financial Inc. now owns 408,937 shares of the biopharmaceutical company’s stock valued at $31,197,000 after buying an additional 34,491 shares during the last quarter. Northwest & Ethical Investments L.P. grew its position in Insmed by 42.9% during the first quarter. Northwest & Ethical Investments L.P. now owns 1,500 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 450 shares in the last quarter. Wellington Management Group LLP grew its position in Insmed by 62.5% during the first quarter. Wellington Management Group LLP now owns 1,222,627 shares of the biopharmaceutical company’s stock worth $93,274,000 after buying an additional 470,401 shares in the last quarter. Hsbc Holdings PLC lifted its position in shares of Insmed by 1.5% in the 1st quarter. Hsbc Holdings PLC now owns 21,423 shares of the biopharmaceutical company’s stock worth $1,613,000 after acquiring an additional 315 shares during the period. Finally, EntryPoint Capital LLC raised its stake in shares of Insmed by 22.9% in the first quarter. EntryPoint Capital LLC now owns 3,997 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 745 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.